Revolade 25Tablet

Indications of Revolade 25 Tablet

Chronic Immune (Idiopathic) Thrombocytopenia, Chronic Hepatitis C-associated Thrombocytopenia, and Severe Aplastic Anemia are all indications for Eltrombopag Olamine.

Pharmacology of Revolade 25 Tablet

Eltrombopag is an orally accessible, small-molecule TPO-receptor agonist that interacts with the human TPO-transmembrane receptor's region. Eltrombopag promotes STAT and JAK phosphorylation. Eltrombopag, unlike recombinant TPO or romiplostim, has no effect on the AKT pathway. It should be emphasized that when eltrombopag was administered to patients with aplastic anemia, other lineages besides platelet count were raised, suggesting that either eltrombopag improved the impact of TPO in vivo, or there is a mechanism of action that has yet to be discovered.

Dosage & Administration of Revolade 25 Tablet

Chronic Immune (Idiopathic) Thrombocytopenia-

Adult and Pediatric Patients 6 Years and Older with ITP: Initiate Eltrombopag at a dose of 50 mg once daily, except in patients who are of East Asian ancestry (such as Chinese, Japanese, Taiwanese or Korean) or who have mild to severe hepatic impairment (Child-Pugh Class A,B,C). For patients of East Asian ancestry with ITP, initiate Eltrombopag at a reduced dose of 25 mg once daily. For patients with ITP and mild, moderate or severe hepatic impairment (Child-Pugh Class A,B,C), initiate Eltrombopag at a reduced dose of 25 mg once daily.

For patients of East Asian ancestry with ITP and hepatic impairment (Child-Pugh Class A,B,C), consider initiating Eltrombopag at a reduced dose of 12.5 mg once daily. Pediatric Patients with ITP Aged 1 to 5 Years: Initiate Eltrombopag at a dose of 25 mg once daily.

Chronic Hepatitis C-associated Thrombocytopenia-

Initiate Eltrombopag at a dose of 25 mg once daily. Monitoring and Dose Adjustment: Adjust the dose of Eltrombopag in 25-mg increments every 2 weeks as necessary to achieve the target platelet count required to initiate antiviral therapy. Monitor platelet counts every week prior to starting antiviral therapy. During antiviral therapy, adjust the dose of Eltrombopag to avoid dose reductions of Peginterferon. Monitor CBCs with differentials, including platelet counts, weekly during antiviral therapy until a stable platelet count is achieved. Monitor platelet counts monthly thereafter. Do not exceed a dose of 100 mg daily. Monitor clinical hematology and liver tests regularly throughout therapy with Eltrombopag.

Severe Aplastic Anemia-

Initiate Eltrombopag at a dose of 50 mg once daily. For patients with severe aplastic anemia of East Asian ancestry or those with mild, moderate or severe hepatic impairment (Child-Pugh Class A,B,C), initiate Eltrombopag at a reduced dose of 25 mg once daily.

Interaction of Revolade 25 Tablet

Eltrombopag should be used at least 2 hours before or 4 hours after any polyvalent cation-containing medicines or products, such as antacids, calcium-rich meals, and mineral supplements.

Contraindications

Eltrombopag has no known side effects.

Side Effects of Revolade 25 Tablet

When used to treat chronic ITP, the most frequent adverse effects of Eltrombopag in adults are: The most prevalent adverse effects in adult ITP patients (more than or equal to 5% and greater than placebo) were nausea, diarrhea, upper respiratory tract infection, vomiting, elevated ALT, myalgia, and urinary tract infection. Upper respiratory tract infection and nasopharyngitis were the most prevalent adverse events (more than or equal to 10% and greater than placebo) in pediatric patients with ITP aged one year and older.

The most common adverse reactions (greater than or equal to 10% and greater than placebo) in patients with chronic hepatitis C-associated thrombocytopenia were anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema. The most prevalent adverse effects (more than or equal to 20%) in patients with severe aplastic anemia were nausea, tiredness, cough, diarrhea, and headache.

Pregnancy & Lactation

Pregnancy Type C. There have been no appropriate and well-controlled research on the use of Eltrombopag during pregnancy. At maternally hazardous levels, there was indications of embryolethality and decreased fetal weights in animal reproductive and developmental toxicity tests. Only if the possible benefit to the mother outweighs the potential risk to the fetus should eltrombopag be taken during pregnancy.

Eltrombopag is not known to be excreted in human milk by nursing mothers. Because many medicines are excreted in human milk and because Eltrombopag has the potential for significant adverse effects in nursing infants, a choice should be taken whether to cease breastfeeding or Eltrombopag, taking into consideration the value of Eltrombopag to the mother.

Precautions & Warnings

Hepatotoxicity: Keep an eye on your liver function before and throughout treatment.

Thrombotic or thromboembolic Complications: Portal vein thrombosis has been documented in Eltrombopag-treated individuals with chronic liver disease. Platelet counts should be checked on a regular basis.

Therapeutic Class

Haemostatic medications

Storage Conditions

Keep away from light and moisture in a cool, dry area. Keep out of children's reach.

Pharmaceutical Name of Revolade 25 Tablet

Glaxo Smithkline Bangladesh Limited

Generic of Revolade 25 Tablet

Eltrombopag Olamine